

INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

MEETING MINUTES

Meeting Date: Tuesday, October 6, 2026
Time: 1:00 pm Eastern Time
Location: Zoom Teleconference
Institution: Neurology Associates, P.A., Maitland, FL
Principal Investigator: Adam Slansky, MD
Protocol: Cartesian Therapeutics, Inc., RNAC-MG-002
NCT Number: NCT06799247
Meeting Type: Continuing Review of Protocol and Site
Title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Descartes-08 in Patients with Generalized Myasthenia Gravis (MG)

1. Call to order:

The Meeting was called to order at 12:59 pm Eastern Time.

2. Introductions and orientation:

Introductions were made and the Chair oriented members to the meeting procedures.

3. Declaration of quorum:

Four voting members were present, including one local member unaffiliated with the institution. Also present was one Institutional Representative and IBC Services staff. The Chair declared that a quorum was present.

4. Conflict of Interest:

The Chair requested that voting members report any conflict of interest regarding this meeting. No conflicts of interest were reported.

5. Public posting:

The Institutional Representative confirmed that notice of the meeting was publicly posted. No public comments were received by the site or the Committee regarding this review.

6. Approval of previous meeting minutes:

Minutes Approved - YES: 4 NO: 0 ABSTAIN: 0

7. Review of proposed research:

The Chair provided an overview of the protocol and status of the study.

The Chair noted changes since the last review.

8. Determination for biosafety level and period of IBC oversight:

The Committee previously determined that **BSL-2 containment facilities and practices** are required for Descartes-08, since it consists of primary human cells modified via mRNA transfection. The Committee reaffirmed this determination.

The Committee previously determined that IBC oversight will continue for **3 months after the last subject's last dose of Descartes-08 locally**, provided that other biosafety criteria for study closure are also met. The Committee reaffirmed this determination.

9. Vote on the Protocol:

The Committee voted for the following determination on the Protocol:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 4

NO: 0

ABSTAIN: 0

INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

10. Review of proposed facilities and practices:

The Chair provided an overview of the arrangement for the facilities and practices.

Points of Discussion:

1. The Committee recommended that an updated photo of the overall view of the Lab/Medication Room, showing the study agent storage unit labeled with a biohazard symbol, be provided to IBC Services.
2. The Committee recommended that a biohazardous waste container for disposal of used PPE and other non-sharps items be placed inside Exam Room #2 and that a photo of this container be provided to IBC Services. The Committee noted that this could be a small, covered trash can labeled with a biohazard symbol and lined with a biohazard bag as the Institutional Representative noted that there is not enough space in the room for the large biohazardous waste box.
3. The Committee recommended that the heat block be labeled with a biohazard symbol and that an updated photo be provided to IBC Services.
4. The Institutional Representative confirmed that Slide #7 in the Photos document labeled as "Dosing Rooms" represents the Infusion Room. The Committee recommended that the photo title be revised accordingly.
5. The Committee recommended that the Biohazard Sign be revised with the correct spelling of the Principal Investigator's last name.
6. The Institutional Representative confirmed that Lysol is not used as a primary disinfectant.

11. Site requirements:

The Chair reviewed training and communication requirements for maintaining IBC approval with the Institutional Representative.

12. Vote on the Site:

The Committee voted for the following determination on the Site:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 4

NO: 0

ABSTAIN: 0

13. Advice to the Institution: None.

14. Meeting adjourned: The meeting was adjourned at 1:12 pm Eastern Time.

15. Post-meeting notes: None.

Documents reviewed:

Agenda

Protocol, Version 1.2, dated 03-13-2026

Protocol Clarification Letter, dated 08-03-2026

Investigator Brochure, Edition 6, dated 12-19-2025

Handling, Storage, and Administration Instructions, Edition 11, dated 12-05-2024

Research Modification Evaluation, Protocol, Version 1.2

Research Modification Evaluation, Protocol Clarification Letter, dated 08-03-2026,

Research Modification Evaluation, Investigator Brochure, Edition 6

Biological Risk Assessment and Summary, updated 08-26-2026

Site Map, dated 09-19-2025

Site Inspection Checklist, expires 09-19-2027, dated 09-19-2025

Photos, dated 09-29-2026

Biohazard Sign, Descartes-08, dated 09-22-2025

SOP, Biosafety for Descartes-08, dated 09-08-2025

Training, Shipping Certification, dated 06-25-2025

CRRF, dated 07-01-2026

Prior Meeting Minutes, Initial, dated 10-06-2025